Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
News from the UK Stock Exchange

Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Arrowhead Pharmaceuticals Inc. - news published 370 - readings 9.932

BACK

Arrowhead Pharmaceuticals Inc.

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders The following proposals were submitted to the stockholders of Arrowhead Pharmaceuticals, Inc. (the "Company") at the 2025 Annual Meeting of Stockholders held on March 12, 2025: • To elect eight directors to serve as members of the Company's Board of Directors until the next Annual Meeting or until their ...

19.03.2025

Arrowhead Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSIO ...

17.03.2025

Arrowhead Pharmaceuticals Inc.

Supplemental Prospectus (Form 424B7)

Table of Contents Filed Pursuant to Rule 424(b)(7) Registration Statement No. 333-268665 PROSPECTUS SUPPLEMENT (To Prospectus dated December 5, 2022) 11,926,301 Shares Common Stock Pursuant to this prospectus supplement, the selling stockholder identified herein (the Selling Stockholder) is offering on a resale basis an aggregate of 11,926,301 shares (the Shares) of co ...

07.03.2025

Arrowhead Pharmaceuticals Inc.

RNA Leaders Europe 2025 Obesity View Presentation

RNA Leaders Congress Targeting Obesity with RNAi-based Therapies March 6, 2025 TRiM Platform: Targeted RNAi Molecule Rules and algorithms to optimize RNAi trigger sequence selection and chemical modification patterns Maximize activity, minimize off-target risk, and disallow miRNA homology More focus on extra-hepatic delivery , leading to a library of PK/PD enhancers , linker c ...

06.03.2025

Arrowhead Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

05.03.2025

Arrowhead Pharmaceuticals Inc.

Keystone Symposia on Obesity and Adipose View Presentation

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Arrowhead Pharmaceuticals Inc. published this content on February 25, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on February 25, 2025 at 13:07:22.659 .

25.02.2025

Arrowhead Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

10.02.2025

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals 2025 First Quarter Results Prepared Remarks

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Arrowhead Pharmaceuticals Inc. published this content on February 10, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on February 10, 2025 at 23:15:13.078 .

10.02.2025

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

- Conference Call and Webcast Today, February 10, 2025, at 4:30 p.m. ET PASADENA, Calif.-(BUSINESS WIRE)-Feb. 10, 2025- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, 2025, at 4:30 p.m. ET to discuss the results. "During ...

10.02.2025

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results (Form 8-K)

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results Conference Call and Webcast Today, February 10, 2025 at 4:30 p.m. ET PASADENA, Calif., Feb. 10, 2025 - Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, 2025, a ...

10.02.2025

Arrowhead Pharmaceuticals Inc.

Quarterly Report for Quarter Ending December 31, 2024 (Form 10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________ FORM 10-Q _____________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC ...

10.02.2025

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

PASADENA, Calif.-(BUSINESS WIRE)-Feb. 10, 2025- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Ant ...

10.02.2025

Arrowhead Pharmaceuticals Inc.

Initial Statement of Beneficial Ownership (Form 3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5 (Print or Type Responses) 1. Nam ...

07.02.2025

Arrowhead Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

07.02.2025

Arrowhead Pharmaceuticals Inc.

Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Douglas Ingram as a Director On February 5, 2025, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the "Company") appointed Douglas Ingram as a director of the Company, effective February ...

07.02.2025

Arrowhead Pharmaceuticals Inc. - news published 370 - readings 9.932

Arrowhead Pharmaceuticals Inc.

Proxy Results (Form 8-K)

Arrowhead Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Arrowhead Pharmaceuticals Inc.

Supplemental Prospectus (Form 424B7)

Arrowhead Pharmaceuticals Inc.

RNA Leaders Europe 2025 Obesity View Presentation

Arrowhead Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Arrowhead Pharmaceuticals Inc.

Keystone Symposia on Obesity and Adipose View Presentation

Arrowhead Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals 2025 First Quarter Results Prepared Remarks

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results (Form 8-K)

Arrowhead Pharmaceuticals Inc.

Quarterly Report for Quarter Ending December 31, 2024 (Form 10-Q)

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

Arrowhead Pharmaceuticals Inc.

Initial Statement of Beneficial Ownership (Form 3)

Arrowhead Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Arrowhead Pharmaceuticals Inc.

Management Change/Compensation (Form 8-K)

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member